LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | A443654 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1914 | 4223 | 0.4532 | 0.1816 |
| SK-BR-3 | OSI-027 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3017 | 4223 | 0.7144 | 0.5726 |
| SK-BR-3 | XMD11-85h | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3250 | 4223 | 0.7697 | 0.6554 |
| SK-BR-3 | HG-6-64-01 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 4507 | 4223 | 1.0674 | 1.1009 |
| SK-BR-3 | WH-4-025 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4737 | 4223 | 1.1218 | 1.1823 |
| SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 2442 | 4223 | 0.5783 | 0.3689 |
| SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 1628 | 4223 | 0.3856 | 0.0804 |
| SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4177 | 4223 | 0.9891 | 0.9837 |
| SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3630 | 4223 | 0.8596 | 0.7899 |
| SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3599 | 4223 | 0.8524 | 0.7791 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1885 | 4223 | 0.4464 | 0.1714 |
| SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3226 | 4223 | 0.7640 | 0.6467 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4452 | 4223 | 1.0542 | 1.0811 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 1099 | 4223 | 0.2602 | -0.1072 |
| SK-BR-3 | CHIR-99021 | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3730 | 4223 | 0.8832 | 0.8252 |
| SK-BR-3 | CP724714 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3625 | 4223 | 0.8585 | 0.7883 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4863 | 4223 | 1.1516 | 1.2269 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3728 | 4223 | 0.8828 | 0.8245 |
| SK-BR-3 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4164 | 4223 | 0.9861 | 0.9792 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4423 | 4223 | 1.0473 | 1.0709 |
| SK-BR-3 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1401 | 3799 | 4223 | 0.8997 | 0.8499 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3691 | 4223 | 0.8742 | 0.8117 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4260 | 4223 | 1.0087 | 1.0131 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 3713 | 4223 | 0.8792 | 0.8192 |
| SK-BR-3 | Foretinib | 0.04 | uM | LJP5 | 72 | hr | 1401 | 4620 | 4223 | 1.0941 | 1.1409 |